BACKGROUND:Insomnia and depression are highly comorbid and mutually exacerbate clinical trajectories and outcomes. Cognitive behavioral therapy for insomnia (CBT-I) effectively reduces both insomnia and depression severity, and can be delivered digitally. This could substantially increase the accessibility to CBT-I, which could reduce the health disparities related to insomnia; however, the efficacy of digital CBT-I (dCBT-I) across a range of demographic groups has not yet been adequately examined. This randomized placebo-controlled trial examined the efficacy of dCBT-I in reducing both insomnia and depression across a wide range of demographic groups. METHODS: Of 1358 individuals with insomnia randomized, a final sample of 358 were retained in the dCBT-I condition and 300 in the online sleep education condition. Severity of insomnia and depression was examined as a dependent variable. Race, socioeconomic status (SES; household income and education), gender, and age were also tested as independent moderators of treatment effects. RESULTS: The dCBT-I condition yielded greater reductions in both insomnia and depression severity than sleep education, with significantly higher rates of remission following treatment. Demographic variables (i.e. income, race, sex, age, education) were not significant moderators of the treatment effects, suggesting that dCBT-I is comparably efficacious across a wide range of demographic groups. Furthermore, while differences in attrition were found based on SES, attrition did not differ between white and black participants. CONCLUSIONS: Results provide evidence that the wide dissemination of dCBT-I may effectively target both insomnia and comorbid depression across a wide spectrum of the population.
RCT Entities:
BACKGROUND:Insomnia and depression are highly comorbid and mutually exacerbate clinical trajectories and outcomes. Cognitive behavioral therapy for insomnia (CBT-I) effectively reduces both insomnia and depression severity, and can be delivered digitally. This could substantially increase the accessibility to CBT-I, which could reduce the health disparities related to insomnia; however, the efficacy of digital CBT-I (dCBT-I) across a range of demographic groups has not yet been adequately examined. This randomized placebo-controlled trial examined the efficacy of dCBT-I in reducing both insomnia and depression across a wide range of demographic groups. METHODS: Of 1358 individuals with insomnia randomized, a final sample of 358 were retained in the dCBT-I condition and 300 in the online sleep education condition. Severity of insomnia and depression was examined as a dependent variable. Race, socioeconomic status (SES; household income and education), gender, and age were also tested as independent moderators of treatment effects. RESULTS: The dCBT-I condition yielded greater reductions in both insomnia and depression severity than sleep education, with significantly higher rates of remission following treatment. Demographic variables (i.e. income, race, sex, age, education) were not significant moderators of the treatment effects, suggesting that dCBT-I is comparably efficacious across a wide range of demographic groups. Furthermore, while differences in attrition were found based on SES, attrition did not differ between white and black participants. CONCLUSIONS: Results provide evidence that the wide dissemination of dCBT-I may effectively target both insomnia and comorbid depression across a wide spectrum of the population.
Authors: Alfred Lange; Deirdre Rietdijk; Milena Hudcovicova; Jean-Pierre van de Ven; Bart Schrieken; Paul M G Emmelkamp Journal: J Consult Clin Psychol Date: 2003-10
Authors: Philip J Batterham; Helen Christensen; Andrew J Mackinnon; John A Gosling; Frances P Thorndike; Lee M Ritterband; Nick Glozier; Kathleen M Griffiths Journal: BJPsych Open Date: 2017-09-25
Authors: David A Kalmbach; Philip Cheng; Louise M O'Brien; Leslie M Swanson; Roopina Sangha; Srijan Sen; Constance Guille; Andrea Cuamatzi-Castelan; Alasdair L Henry; Thomas Roth; Christopher L Drake Journal: Sleep Med Date: 2020-03-21 Impact factor: 3.492
Authors: David A Kalmbach; James L Abelson; J Todd Arnedt; Zhuo Zhao; Jessica R Schubert; Srijan Sen Journal: Sleep Med Date: 2018-12-14 Impact factor: 3.492
Authors: Philip Cheng; David A Kalmbach; Gabriel Tallent; Christine Lm Joseph; Colin A Espie; Christopher L Drake Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Philip Cheng; David A Kalmbach; Hsing-Fang Hsieh; Andrea Cuamatzi Castelan; Chaewon Sagong; Christopher L Drake Journal: Psychol Med Date: 2022-03-08 Impact factor: 10.592
Authors: Colin A Espie; Richard Emsley; Simon D Kyle; Christopher Gordon; Christopher L Drake; A Niroshan Siriwardena; John Cape; Jason C Ong; Bryony Sheaves; Russell Foster; Daniel Freeman; Joan Costa-Font; Antonia Marsden; Annemarie I Luik Journal: JAMA Psychiatry Date: 2019-01-01 Impact factor: 21.596
Authors: Joy Sun; Miranda V McPhillips; Ker-Cheng Chen; Yinyin Zang; Junxin Li; Jessica Oehlke; Glenna S Brewster; Nalaka S Gooneratne Journal: J Clin Sleep Med Date: 2021-05-01 Impact factor: 4.062
Authors: Nayra A Martin-Key; Benedetta Spadaro; Erin Funnell; Eleanor Jane Barker; Thea Sofie Schei; Jakub Tomasik; Sabine Bahn Journal: JMIR Ment Health Date: 2022-03-30